We are a clinical stage oncology company and industry leader in microbiome restoration therapy using biotherapeutics, made of a high diversity microbiome, to treat life-threatening diseases.
We are a clinical stage oncology company and industry leader in microbiome restoration therapy which has demonstrated safety and restoration of both immune homeostasis and gut barrier integrity in a Phase 1a/2b trial in AML patients. As an initial focus, we are committed to improving overall survival in blood cancers and graft-versus-host disease. We have established the MMRB (MaaT Microbiome Restoration Biotherapeutics) integrative platform to develop our lead product, determine novel disease targets and identify biomarkers for microbiome-related conditions. We benefit from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
We are developing a novel class of off-the-shelf biological drugs to create disease-specific microbiome restoration therapeutics. We are focusing initially on onco-hematology, our most advance program is directed toward Acute Myeloid Leukemia, a disease for which overall five-year survival rate is very low (approx.25%).
We have established MMRB (MaaT Microbiome Restoration Biotherapeutics) as an industry-leading integrated platform for the development of biotherapeutics and to provide for the characterization of the microbiome thanks to our proprietary big data analytics pipeline (GutPrint®).
MMRB represents the first proprietary platform in Europe for microbiome-based biotherapeutics.
Strategic Partnerships to Advance Microbiome Biotherapeutics
Our diverse group of partners enables us to accelerate the promise of microbiome science to deliver first-in-class biotherapeutics for patients. We have established strategic partnerships with pharmaceutical companies and research institutes with therapeutic area expertise, leveraging our MMRB platform. These relationships and our ongoing dialogue with regulators worldwide produce an ecosystem for our success.
Most recent News
MaaT Pharma Presents Positive Updated Results with its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute GvHD at ASH 2020 Annual Meeting
Partnering with MaaT Pharma
to accelerate the access of our drugs to patients.
We are constantly looking to explore new frontiers, improve our drugs and improve the preparation of our clinical trials. Therefore, we are open to partnerships with investigator-initiated studies to collect Big Data using our GutPrint® meta genomics platform.